Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Issa Yusuf

Internal Medicine Mitchellville, MD Medical Doctor

NPI 1912934571 CMS profile 358814

12164 Central Ave, Suite #223, Mitchellville, MD 20721

Open in the dashboard

General payments

$1,383

23 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$349,998 paid to institutions, not to them · program years 2022–2025

Through program year 2025, Issa Yusuf of Mitchellville, MD is reported in the CMS Open Payments database as having received $1,383 across 23 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $349,998 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 74th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $97 6
2024 General $103 5
2023 General $1,170 11
2022 General $14 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Issa Yusuf
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Issa Yusuf were reported at $97. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Issa Yusuf Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $14 $141 $42–$496 $149
2023 $1,170 $149 $45–$519 $160
2024 $103 $154 $47–$537 $164
2025 $97 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Novartis Pharmaceuticals Corporation $1,126 9 payments
  2. Amgen Inc. $81 5 payments
  3. Abbott Laboratories $60 3 payments
  4. AstraZeneca Pharmaceuticals LP $39 2 payments
  5. Novo Nordisk Inc $35 2 payments
  6. Astellas Pharma US Inc $23 1 payment
  7. Pfizer Inc. $20 1 payment

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Travel and Lodging $752 5 payments
  2. Food and Beverage $631 18 payments
Products named General payments · program years 2022–2025
  1. LEQVIO $1,112 8 payments
  2. Otezla $81 5 payments
  3. REPATHA $63 4 payments
  4. AIRSUPRA $39 2 payments
  5. FreeStyle Libre 3 $38 2 payments
  6. RYBELSUS $35 2 payments
  7. Ozempic $35 2 payments
  8. Veozah $23 1 payment
  9. FreeStyle Libre 2 $22 1 payment
  10. PREVNAR 20 $20 1 payment
  11. Other $98 6 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 41 drugs

Part D claims

1,454

Median for Internal Medicine: 777

Drug cost

$173,135

Median for Internal Medicine: $73,373

Branded share of claims

28.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 67 $72,263
Mounjaro Tirzepatide Brand 25 $29,449
Janumet Sitagliptin Phos/Metformin Hcl Brand 22 $17,384
Jardiance Empagliflozin Brand 15 $15,501
Carvedilol Er Carvedilol Phosphate Brand 24 $12,231
Valsartan-Hydrochlorothiazide Valsartan/Hydrochlorothiazide Brand 67 $4,724
Atorvastatin Calcium Generic 196 $2,573
Rosuvastatin Calcium Generic 129 $2,281
Olmesartan-Amlodipine-Hctz Olmesartan/Amlodipin/Hcthiazid Brand 11 $2,157
Metoprolol Succinate Generic 69 $1,541

The 10 drugs with the highest cost, of 41 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$188,216

Of which drugs: $46,561

Medicare patients

207

Average age 74

Services billed

3,032

119 women, 88 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 59%
Arthritis 47%
Chronic kidney disease 44%
Diabetes 42%
Osteoporosis 27%
Ischemic heart disease 22%
COPD 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 59 60 $17,233
Sarscov2 vac 50 mcg/0.5ml im 91322 Office 96 97 $14,957
Vaccine for influenza for injection into muscle 90653 Office 122 122 $9,737
Influenza virus vaccine, quadrivalent (aiiv4), inactivated, adjuvanted, preservative free, for injection into muscle, 0.5 ml dosage 90694 Office 12 12 $834

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $39
$39 — —
Otezla
  • Amgen Inc. $9
$9 — —
Repatha
  • Amgen Inc. $9
$9 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

23 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record